Основная статистика
| CIK | 1837493 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Inspira Technologies Oxy B.H.N. Ltd. - Equity Warrant
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| September 2, 2025 |
Top U.S. Honor Roll Hospital Expands Use of INSPIRA™ ART100 System to Lung Transplant Procedures Exhibit 99.1 Top U.S. Honor Roll Hospital Expands Use of INSPIRA™ ART100 System to Lung Transplant Procedures RA’ANANA, Israel, September 2, 2025 - Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira,” “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced that a top U.S. hospital, has expanded its clinical use of the |
|
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2025 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of princi |
|
| August 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2025 (Report No. 2) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addre |
|
| August 22, 2025 |
Exhibit 99.1 Inspira Receives U.S. Patent Approval for the ART500 Core Technology, Key Patent Positions the Company to Dominate $20 Billion Estimated Market RA’ANANA, Israel, August 22, 2025 - Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira,” “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, has received U.S. Patent approval |
|
| August 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2025 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of principal |
|
| August 19, 2025 |
Exhibit 99.1 Inspira Secures $27 Million Government Binding Purchase Order for ART100 Systems with Full Payment in 2025 RA’ANANA, Israel, August 19, 2025 - Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira,” “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced that a national ministry of health in Africa (the “Min |
|
| August 6, 2025 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES F-3 INSPIRA TECHNOLOGIES OXY B.H.N. LTD. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity |
|
| August 6, 2025 |
As filed with the Securities and Exchange Commission on August 6, 2025 As filed with the Securities and Exchange Commission on August 6, 2025 Registration No. |
|
| July 31, 2025 |
Inspira Activates U.S. Based Consulting Firm to Execute Transformational Initiatives Exhibit 99.1 Inspira Activates U.S. Based Consulting Firm to Execute Transformational Initiatives RA’ANANA, Israel, July 31, 2025 - Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira,” “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced that it has activated a leading consulting firm to accelerate high-impact exec |
|
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2025 (Report No. 7) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address |
|
| July 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2025 (Report No. 6) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address |
|
| July 18, 2025 |
Inspira Regains Compliance with Nasdaq Minimum Bid Price Requirement Exhibit 99.1 Inspira Regains Compliance with Nasdaq Minimum Bid Price Requirement RA’ANANA, Israel, July 18, 2025 - Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira,” “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced that it has received formal notification from The Nasdaq Stock Market LLC (“Nasdaq”) confirmin |
|
| July 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2025 (Report No. 5) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address |
|
| July 10, 2025 |
Exhibit 99.1 Inspira Achieves All Key Objectives in Previously Announced Government Talks, Forging a Pathway to National Adoption and Global Scale-Up of the ART100 RA’ANANA, Israel, July 10, 2025 - Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN,IINNW) (“Inspira,” “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced it has |
|
| July 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2025 (Report No. 4) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address |
|
| July 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2025 (Report No. 3) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address |
|
| July 7, 2025 |
Exhibit 99.1 Inspira in High-Level Government Talks to Advance National Integration of the ART100 and Establish a Global Distribution Framework RA’ANANA, Israel, July 7, 2025 - Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira,” “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced that it is engaged in high-level |
|
| July 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2025 (Report No. 2) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address |
|
| July 2, 2025 |
Inspira Technologies Secures $22.5 Million Purchase Order, Launches Full Revenue Execution Phase Exhibit 99.1 Inspira Technologies Secures $22.5 Million Purchase Order, Launches Full Revenue Execution Phase RA’ANANA, Israel, July 2, 2025 - Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira,” “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced it has secured a binding $22.5 million purchase order for its FDA-c |
|
| July 1, 2025 |
Up to $7,117,720 Ordinary Shares Filed Pursuant to Rule 424(b)(5) Registration No. 333-266748 AMENDMENT NO. 2 DATED JULY 1, 2025 To Prospectus Supplement dated March 14, 2025 (to Prospectus dated August 18, 2022) Up to $7,117,720 Ordinary Shares This Amendment No. 2, or the Amendment, amends and supplements the information in the prospectus, dated August 18, 2022, filed with the Securities and Exchange Commission as a part of our |
|
| July 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: July 2025 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of principal |
|
| June 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: June 2025 (Report No. 3) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addres |
|
| June 11, 2025 |
Exhibit 99.1 Inspira’s ART100 in Use at Tier-1 U.S. Hospitals, Generating Strong Clinical Interest and Accelerating Sales Discussions RA’ANANA, Israel, June 11, 2025 - Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira,” “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, announced today that its FDA-cleared ART100 system adoptio |
|
| June 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2025 (Report No. 2) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address |
|
| June 5, 2025 |
Exhibit 99.1 Inspira Scales Up ART100 Production Capabilities Amid Advanced Negotiation with European Government Authority RA’ANANA, Israel, June 5, 2025 - Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira,” “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced that it has scaled-up its production capabilities for |
|
| June 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2025 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of principal e |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: May 2025 (Report No. 5) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address |
|
| May 30, 2025 |
INSPIRA TECHNOLOGIES OXY B.H.N. Ltd. NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Exhibit 99.1 INSPIRA TECHNOLOGIES OXY B.H.N. Ltd. NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that an Extraordinary General Meeting of Shareholders (the “Meeting”) of Inspira Technologies Oxy B.H.N. Ltd. (“Inspira Technologies” or the “Company”) will be held on June 20, 2025 at 3:00 p.m. Israel time at the Company’s office, located at 2 Ha-Tidhar Street, Ra’anana |
|
| May 29, 2025 |
Exhibit 99.1 Inspira Technologies Initiates Global Commercial Rollout of FDA-Cleared ART100 System Following successful clinical implementations in the U.S., Inspira accelerates commercialization of its system. The Company is already engaged in discussions with governmental health departments and private organizations RA’ANANA, Israel, May 29, 2025 - Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: |
|
| May 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2025 (Report No. 4) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address |
|
| May 27, 2025 |
Inspira Technologies Aligns Executive Team Amid Corporate Structuring Initiatives Exhibit 99.1 Inspira Technologies Aligns Executive Team Amid Corporate Structuring Initiatives RA’ANANA, Israel, May 27, 2025 – Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira” or the “Company”), a pioneering company in advanced respiratory support and diagnostic systems, today announced an evolution in its executive structure that reflects recent internal assessments and long-term |
|
| May 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: May 2025 (Report No. 3) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: May 2025 (Report No. 2) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2025 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of principal ex |
|
| May 7, 2025 |
Exhibit 99.1 INSPIRA ART100 System Approved by Israel’s Largest Healthcare Provider for Use in Organ Transplant Patients RA’ANANA, Israel, May 7, 2025 - Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced that the INSPIRA™ ART100 has been approved by Israel’s largest healthcare provider |
|
| April 23, 2025 |
Inspira Achieves above 99% Gas Exchange Efficiency in VORTX™ Technology In Vivo Animal Testing Exhibit 99.1 Inspira Achieves above 99% Gas Exchange Efficiency in VORTX™ Technology In Vivo Animal Testing RA’ANANA, Israel, April 23, 2025 - Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (“Inspira” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced a major milestone achievement in the in-vivo testing of its next-generation VORTX™ te |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2025 (Report No. 5) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addres |
|
| April 15, 2025 |
Inspira Technologies Generates First Revenues from Deployment of INSPIRA ART100 Systems Exhibit 99.1 Inspira Technologies Generates First Revenues from Deployment of INSPIRA ART100 Systems The Company achieves significant milestone with initial revenues generated from FDA-cleared life support technology deployed in a leading U.S. healthcare facility; additional systems currently planned for second hospital facility RA’ANANA, Israel, April 15, 2025 - Inspira™ Technologies OXY B.H.N. L |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2025 (Report No. 4) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addres |
|
| April 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: April 2025 (Report No. 3) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addre |
|
| April 10, 2025 |
Up to $1,917,052 Ordinary Shares Filed Pursuant to Rule 424(b)(5) Registration No. 333-266748 PROSPECTUS SUPPLEMENT To Prospectus Supplement dated March 14, 2025 (to Prospectus dated August 18, 2022) Up to $1,917,052 Ordinary Shares This prospectus supplement amends and supplements the information in the prospectus, dated August 18, 2022, filed with the Securities and Exchange Commission as a part of our registration statement on |
|
| April 7, 2025 |
Exhibit 99.1 Inspira Technologies Announces Successful Treatment of First Patient with INSPIRA ART100 at Westchester Medical Center First Clinical Use of INSPIRA ART100 System Successfully Completes Full Treatment Cycle, Validating the Technology’s Performance in a Real-World Clinical Environment and Garnering Overwhelmingly Positive Feedback RA’ANANA, Israel, April 07, 2025 - Inspira™ Technologie |
|
| April 7, 2025 |
INSPIRA TECHNOLOGIES OXY B.H.N. Ltd. NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Exhibit 99.1 INSPIRA TECHNOLOGIES OXY B.H.N. Ltd. NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that an Extraordinary General Meeting of Shareholders (the “Meeting”) of Inspira Technologies Oxy B.H.N. Ltd. (the “Company”) will be held on May 12, 2025, at 4:00 p.m. Israel time at the Company’s office, located at 2 Ha-Tidhar Street, Ra’anana 4366504, Israel. The Meet |
|
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2025 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of principal |
|
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: April 2025 (Report No. 2) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addre |
|
| March 28, 2025 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) Exhibit 12.1 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Dagi Ben-Noon, certify that: 1. I have reviewed this annual report on Form 20-F/A of Inspira Technologies Oxy B.H.N. Ltd. (the “company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of |
|
| March 28, 2025 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) Exhibit 12.2 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Yafit Tehila, certify that: 1. I have reviewed this annual report on Form 20-F/A of Inspira Technologies Oxy B.H.N. Ltd. (the “company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of |
|
| March 28, 2025 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F/A for the period ended December 31, 2024 (the “Report”) by Inspira Technologies Oxy B.H.N. Ltd. (the “company”), the undersigned, as the Chief Financial Officer of the company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report fully |
|
| March 28, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Inspira Technologies Oxy B.H.N. Ltd. 2 Ha-Tidhar St. Rananna 4366504, Israel We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-259057 and 333-277980) and Form F-3 (Nos. 333-266748 and 333-284308) of Inspira Technologies Oxy B.H.N Ltd (“the Company”) of our report dated March |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F/A (Amendment No. |
|
| March 28, 2025 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F/A for the period ended December 31, 2024 (the “Report”) by Inspira Technologies Oxy B.H.N. Ltd. (the “company”), the undersigned, as the Chief Executive Officer of the company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report fully |
|
| March 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2025 (Report No. 6) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addres |
|
| March 25, 2025 |
Exhibit 99.1 Inspira Technologies Announces Successful Installation of INSPIRA ART100 Systems in Premier U.S. Hospital Inspira’s innovative FDA-cleared INSPIRA™ ART100 system was successfully deployed at premier U.S. hospital, with systems in place for clinical use RA’ANANA, Israel, March 25, 2025 - Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira” or the “Company”), a pioneer in inn |
|
| March 14, 2025 |
6-K 1 ea0234433-6kinspira.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2025 (Report No. 4) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name |
|
| March 14, 2025 |
INSPIRA TECHNOLOGIES OXY B.H.N. LTD. ORDINARY SHARES SALES AGREEMENT Exhibit 99.1 INSPIRA TECHNOLOGIES OXY B.H.N. LTD. ORDINARY SHARES SALES AGREEMENT March 14, 2025 A.G.P./Alliance Global Partners 590 Madison Avenue New York, NY 10022 Ladies and Gentlemen: Inspira Technologies OXY B.H.N. LTD., a company incorporated under the laws of the State of Israel, having its registered office at Puglisi & Associates, 850 Library Ave., Suite 204, Newark, DE 19711 (the “Compa |
|
| March 14, 2025 |
Up to $1,019,000 Ordinary Shares Filed pursuant to Rule 424(b)(5) Registration No. 333-266748 PROSPECTUS SUPPLEMENT (To Prospectus dated August 18, 2022) Up to $1,019,000 Ordinary Shares We have entered into a sales agreement (the “Sales Agreement”) with A.G.P./Alliance Global Partners (“AGP” or the “Sales Agent”), dated March 14, 2025, relating to the sale of our ordinary shares, no par value (“Ordinary Shares”), offered by this |
|
| March 14, 2025 |
Inspira Technologies Releases CEO Update: Major Milestones Signal Next-Level Respiratory Care Exhibit 99.1 Inspira Technologies Releases CEO Update: Major Milestones Signal Next-Level Respiratory Care Letter from the CEO / March 14, 2025 Ra’anana, Israel – March 14, 2025 – Inspira™ Technologies OXY B.H.N. Ltd. (“Inspira,” “Inspira Technologies” or the “Company”) (Nasdaq: IINN), a pioneering force in the evolution of respiratory support and real-time blood-monitoring technologies, is please |
|
| March 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March (Report No. 5) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of |
|
| March 13, 2025 |
Inspira Technologies Receives Nasdaq Notification Regarding Minimum Bid Requirement Exhibit 99.1 Inspira Technologies Receives Nasdaq Notification Regarding Minimum Bid Requirement Ra’anana, Israel – March 13, 2025 – Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (“Inspira” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced that on March 10, 2025, the Company received a written notice (the “Notice”) from the Nasdaq Stock Mar |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2025 (Report No. 3) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addres |
|
| March 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2025 (Report No. 2) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addres |
|
| March 11, 2025 |
Exhibit 99.1 Inspira Technologies Reports Full Year 2024 Financial Results and Provides Business Updates Significant progress in HYLA blood sensor and INSPIRA ART core technologies RA’ANANA, Israel, March 11, 2025 - Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (“Inspira” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced its financial resul |
|
| March 10, 2025 |
Exhibit 2.1 Description of Securities The following description of the share capital of Inspira Technologies Oxy B.H.N. Ltd. (the “Company”, “we”, “us” or “our”), provisions of the Company’s amended and restated articles of association, as they may be amended and restated from time to time (our “Articles”), and Israeli law are summaries and do not purport to be complete, and is qualified in its en |
|
| March 10, 2025 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) Exhibit 12.2 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Yafit Tehila, certify that: 1. I have reviewed this annual report on Form 20–F of Inspira Technologies Oxy B.H.N. Ltd. (the “company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of th |
|
| March 10, 2025 |
Exhibit 11.1(b) INSPIRA TECHNOLOGIES OXY B.H.N. LTD. INSIDER TRADING POLICY AND GUIDELINES WITH RESPECT TO CERTAIN TRANSACTIONS IN COMPANY SECURITIES Date: March 10, 2025 This Insider Trading Policy (the “Policy”) provides guidelines to directors, officers, employees and other related persons of Inspira Technologies Oxy B.H.N. Ltd., an Israeli company (the “Company”), with respect to transactions |
|
| March 10, 2025 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2024 (the “Report”) by Inspira Technologies Oxy B.H.N. Ltd. (the “company”), the undersigned, as the Chief Financial Officer of the company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report fully co |
|
| March 10, 2025 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) Exhibit 12.1 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Dagi Ben-Noon, certify that: 1. I have reviewed this annual report on Form 20–F of Inspira Technologies Oxy B.H.N. Ltd. (the “company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of t |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. |
|
| March 10, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Inspira Technologies Oxy B.H.N. Ltd. 2 Ha-Tidhar St. Rananna 4366504, Israel We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-259057, 333-277980 and 333-285565) and Form F-3 (Nos. 333-266748 and 333-284308) of Inspira Technologies Oxy B.H.N Ltd (“the Company”) of our report |
|
| March 10, 2025 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2024 (the “Report”) by Inspira Technologies Oxy B.H.N. Ltd. (the “company”), the undersigned, as the Chief Executive Officer of the company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report fully co |
|
| March 5, 2025 |
As filed with the Securities and Exchange Commission on March 5, 2025 As filed with the Securities and Exchange Commission on March 5, 2025 Registration No. |
|
| March 5, 2025 |
Exhibit 99.1 Inspira Technologies OXY B.H.N LTD. (Formerly Insense Medical Ltd.) 2019 EQUITY INCENTIVE PLAN (amended on March 4, 2025) 1. Purpose: The purpose of this 2019 Equity Incentive Plan is to provide an additional incentive to Employees, officers, Directors, Consultants and certain other Service Providers of the Company (as defined below) and any Affiliate of the Company (as defined below) |
|
| March 5, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) INSPIRA TECHNOLOGIES OXY B. |
|
| March 4, 2025 |
Exhibit 99.1 Inspira Technologies Announces Positive Results from Clinical Study of HYLA Blood Sensor, Achieving 96% Accuracy Inspira’s AI-powered continuous blood monitoring technology demonstrated a high degree of accuracy in a key parameter, targeting multiple multi-billion-dollar market segments; Company plans to advance with ongoing clinical study following this success; FDA submission planne |
|
| March 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2025 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of principal |
|
| February 11, 2025 |
Exhibit 99.1 Inspira Achieves Positive Results of Above 95% For Preventing Bloodstream Infections The ex-vivo testing demonstrated significant bacterial reduction for the innovative IV dressing technology aimed at preventing bloodstream infections in critical patients Ra’anana, Israel - February 11, 2025 – Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (“Inspira” or the “Company”), a pioneer |
|
| February 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2025 (Report No. 3) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Add |
|
| February 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2025 (Report No. 2) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Add |
|
| February 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2025 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of princip |
|
| February 5, 2025 |
Exhibit 99.1 Inspira Technologies Integrates New Oxygenation Indicator into AI-Powered HYLA Blood Sensor Inspira Technologies develops its innovative AI-powered HYLA technology with advanced blood testing capability, enabling continuous monitoring of tissue oxygenation and early hypoxia detection; Company expects to release preliminary clinical results for the sensor in the near future Ra’anana, I |
|
| January 30, 2025 |
INSPIRA TECHNOLOGIES OXY B.H.N.LTD. Up to 9,217,430 Ordinary Shares Filed Pursuant to Rule 424(b)(4) Registration No. 333-284308 PROSPECTUS PROSPECTUS INSPIRA TECHNOLOGIES OXY B.H.N.LTD. Up to 9,217,430 Ordinary Shares This prospectus relates to the resale, by the selling shareholders identified in this prospectus, up to 9,217,430 ordinary shares, no par value per share, or the Ordinary Shares, consisting of (i) up to 3,950,343 Ordinary Shares held by the selling |
|
| January 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2025 (Report No. 6) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addr |
|
| January 27, 2025 |
Exhibit 99.1 Inspira™ Introduces Advanced Features for INSPIRA™ ART100, Further Amplifying User and System Support Ra’anana, Israel – January 27, 2025 – Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (“Inspira” or the “Company”), a leader in innovative medical technology, has announced the addition of new support features to the INSPIRA™ ART100, a system cleared by the U.S. Food and Dr |
|
| January 22, 2025 |
Inspira Technologies OXY B.H.N. Ltd. 2 Ha-Tidhar St. Ra’anana, 4366504, Israel Inspira Technologies OXY B.H.N. Ltd. 2 Ha-Tidhar St. Ra’anana, 4366504, Israel January 22, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Inspira Technologies OXY B.H.N. Ltd. (CIK: 0001837493) Registration Statement on Form F-3 (File No. 333- 284308) (the “Registration |
|
| January 21, 2025 |
Exhibit 99.1 Inspira™ Announces the Appointment of Tal Parnes as the New Chairman of the Board, Bringing Vast Experience in the Medical Technology and Pharmaceutical Sectors Ra’anana, Israel, January 21, 2025 – Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (“Inspira” or the “Company”), a leader in life-support technology innovation, has announced the appointment of Mr. Tal Parnes as t |
|
| January 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2025 (Report No. 5) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addr |
|
| January 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2025 (Report No. 4) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addr |
|
| January 17, 2025 |
Inspira™ Technologies Collaborates With Zriha Medical To Launch Cutting-Edge Production Line Exhibit 99.1 Inspira™ Technologies Collaborates With Zriha Medical To Launch Cutting-Edge Production Line Ra’anana, Israel, January 17, 2025 – Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (“Inspira” or the “Company”), a leader in life-support technology innovation, has announced that the Company is establishing a dedicated production line for a crucial component of its innovative res |
|
| January 16, 2025 |
As filed with the Securities and Exchange Commission on January 16, 2025 As filed with the Securities and Exchange Commission on January 16, 2025 Registration No. |
|
| January 16, 2025 |
Exhibit 107 Calculation of Filing Fee Table F-3 (Form Type) INSPIRA TECHNOLOGIES OXY B. |
|
| January 14, 2025 |
Inspira™ Technologies Unveils Modular Configuration for Revolutionary VORTX Exhibit 99.1 Inspira™ Technologies Unveils Modular Configuration for Revolutionary VORTX™ Blood Oxygenation Delivery Technology The technology has the potential to provide life-saving support for the approximately 20 million ICU patients with respiratory failure annually Ra’anana, Israel, January 14, 2025 – Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (“Inspira” or the “Company”), a |
|
| January 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2025 (Report No. 3) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addr |
|
| January 10, 2025 |
Inspira™ Preparing Production in Response to Spread of Respiratory Virus in China Exhibit 99.1 Inspira™ Preparing Production in Response to Spread of Respiratory Virus in China Ra’anana, Israel, January 10, 2025 – Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (“Inspira” or the “Company”), a leader in life-support technology innovation, announced today that it is preparing for a potential production ramp-up of its INSPIRA™ ART100 device. This strategic readiness com |
|
| January 10, 2025 |
6-K 1 ea0227344-6kinspira.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2025 (Report No. 2) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s na |
|
| January 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2025 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of principa |
|
| January 7, 2025 |
Exhibit 99.1 Inspira™ Technologies Flagship Technology to be Showcased at Arab Health Expo 2025 in Dubai Visitors at Glo-Med Network Inc’s booth can explore Inspira’s cutting-edge respiratory solutions, with the FDA-cleared INSPIRA™ ART100, showcasing the future of respiratory care RA’ANANA, Israel – January 7, 2025 – Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN, IINNW), (“Inspira Technologi |
|
| December 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: December 2024 (Report No. 5) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Ad |
|
| December 27, 2024 |
Exhibit 99.4 PLACEMENT AGENCY AGREEMENT December 27, 2024 Dawson James Securities, Inc. 101 North Federal Highway, Suite 600 Boca Raton, FL 33432 Ladies and Gentlemen: This letter (this “Agreement”) constitutes the agreement between Inspira Technologies OXY B.H.N. Ltd., a company organized under the laws of the State of Israel (the “Company”) and Dawson James Securities, Inc. (“Dawson” or the “Pla |
|
| December 27, 2024 |
ORDINARY SHARE PURCHASE WARRANT INSPIRA TECHNOLOGIES OXY B.H.N. LTD. Exhibit 99.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| December 27, 2024 |
Exhibit 99.5 Inspira™ Announces Pricing of $3.2 Million Private Placement by New and Existing Investors of the Company RA’ANANA, Israel– December 27, 2024 – Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN, IINNW), (“Inspira Technologies,” “Inspira” or the “Company”), a groundbreaking respiratory support technology company, a pioneer in life-support technology, today announced the pricing of a p |
|
| December 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2024 (Report No. 4) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Add |
|
| December 27, 2024 |
PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT INSPIRA TECHNOLOGIES OXY B.H.N. LTD. Exhibit 99.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| December 27, 2024 |
Exhibit 99.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 27, 2024, between Inspira Technologies OXY B.H.N. Ltd., a company organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchas |
|
| December 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2024 (Report No. 3) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Add |
|
| December 16, 2024 |
Inspira™ Technologies Delivers Systems to Leading Distributor for U.S. Deployment Exhibit 99.1 Inspira™ Technologies Delivers Systems to Leading Distributor for U.S. Deployment RA’ANANA, Israel– December 16, 2024 – Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN, IINNW), (“Inspira Technologies,” “Inspira” or the “Company”), a groundbreaking respiratory support technology company, announced the delivery of INSPIRA™ ART100 systems to its U.S. distributor, Glo-Med Networks Inc |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2024 (Report No. 2) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Add |
|
| December 10, 2024 |
Exhibit 99.1 Inspira™ Expands HYLA™ Blood Sensor Technology into Personalized Blood Lab Testing for Rapid Detection of Serious Medical Conditions RA’ANANA, Israel– December 10, 2024 – Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN, IINNW), (“Inspira Technologies” or the “Company”), a groundbreaking life support technology company, revealed the expansion of its HYLA blood sensor technology (“HY |
|
| December 4, 2024 |
Exhibit 99.1 Inspira™ Collaborates with New York’s Westchester Medical Center to Evaluate the INSPIRA™ ART100 Functionality and Performance in Clinical Scenarios Ra’anana, Israel, December 4, 2024 – Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (“Inspira Technologies”, “Inspira” or the “Company”), a groundbreaking life support technology company, entered into a strategic collaboration |
|
| December 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2024 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of princip |
|
| November 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: November 2024 (Report No. 2) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Ad |
|
| November 25, 2024 |
INSPIRA TECHNOLOGIES OXY B.H.N. Ltd. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS Exhibit 99.1 INSPIRA TECHNOLOGIES OXY B.H.N. Ltd. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that an Annual General Meeting of Shareholders (the “Meeting”) of Inspira Technologies Oxy B.H.N. Ltd. (“Inspira Technologies” or the “Company”) will be held on December 30, 2024, at 4:00 p.m. Israel time at the Company’s office, located at 2 Ha-Tidhar Street, Ra’anana 4366504, |
|
| November 14, 2024 |
IINN / Inspira Technologies Oxy B.H.N. Ltd. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-iinn093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* INSPIRA TECHNOLOGIES OXY B.H.N. LTD. (Name of Issuer) Ordinary Shares, no par value (Title of Class of Securities) M53637100 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) C |
|
| November 12, 2024 |
Exhibit 99.1 See Disclaimers on slides 1 - 16 . Copyright © 2018 - 2024 Inspira Technologies OXY B.H.N. LTD., All rights reserved 1 See Disclaimers in deck on slides 3 Copyright © 2018 - 2024 Inspira Technologies OXY B.H.N. LTD., All rights reserved 1 Inspira Technologies WEBINAR NOVEMBER 2024 See Disclaimers on slides 2 - 3 Copyright © 2018 - 2024 Inspira Technologies OXY B.H.N. LTD., All rights |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2024 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of princip |
|
| October 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2024 (Report No. 2) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addr |
|
| October 24, 2024 |
Exhibit 99.1 Inspira™ Announces Establishment of Distribution Facility to Support U.S. Deployment of INSPIRA™ ART100 The Company has signed a distribution agreement that assigns to Glo-Med the role of Inspira’s primary distributor and customer support center in the U.S. Ra’anana, Israel, October 24, 2024 – Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (“Inspira Technologies”, “Inspira |
|
| October 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2024 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of principa |
|
| October 9, 2024 |
Inspira™ Announces Development of New Disposable Kit with Built-In Performance Monitoring Mechanism Exhibit 99.1 Inspira™ Announces Development of New Disposable Kit with Built-In Performance Monitoring Mechanism Ra’anana, Israel, October 9, 2024 – Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (“Inspira Technologies”, “Inspira” or the “Company”), a groundbreaking respiratory support technology company, is pleased to announce the development of a new disposable kit for the perfusion |
|
| September 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2024 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of princi |
|
| September 13, 2024 |
Inspira™ Secures a Second U.S. Patent Approval for Orbiting Blood Oxygenation Delivery System Exhibit 99.1 Inspira™ Secures a Second U.S. Patent Approval for Orbiting Blood Oxygenation Delivery System To date, a combined total of 32 claims have been deemed novel for the core technology of the INSPIRA™ ART device Targeting treatment for 20 million ICU patients with respiratory failure annually, with many relying on mechanical ventilators, in a $19 billion industry. Ra’anana, Israel, Septemb |
|
| August 29, 2024 |
As filed with the Securities and Exchange Commission on August 29, 2024 As filed with the Securities and Exchange Commission on August 29, 2024 Registration No. |
|
| August 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2024 (Report No. 4) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addre |
|
| August 28, 2024 |
Exhibit 99.1 Inspira™ to Publish HYLA™ Clinical Results in Fourth Quarter 2024 The clip-on HYLA™ blood sensor, designed to alert physicians of immediate signs of changes in a patient’s clinical condition without the need for intermittent actual blood samples, targets a potential $2.5 billion Point of Care testing and Arterial Blood Gas (ABG) analyzer market. Ra’anana, Israel, August 28, 2024 – Ins |
|
| August 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2024 (Report No. 3) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addre |
|
| August 22, 2024 |
Inspira™ Technologies Announces FDA Listing and Market Readiness of New Product Exhibit 99.1 Inspira™ Technologies Announces FDA Listing and Market Readiness of New Product Ra’anana, Israel, August 22, 2024 – Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (“Inspira” or the “Company”), a leader in life-support technology innovation, today announces the U.S. Food and Drug Administration (“FDA”) listing of its medical cart (INSPIRA™ CART) which has been custom design |
|
| August 15, 2024 |
Exhibit 99.1 INSPIRA TECHNOLOGIES OXY B.H.N. LTD. INTERIM CONDENSED FINANCIAL STATEMENTS AS OF JUNE 30, 2024 UNAUDITED INSPIRA TECHNOLOGIES OXY B.H.N. LTD. (UNAUDITED) TABLE OF CONTENTS Page Interim condensed balance sheets 1-2 Interim condensed statements of comprehensive loss 3 Interim condensed statements of changes in shareholders’ equity 4 Interim condensed statements of cash flows 5 Notes to |
|
| August 15, 2024 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Cautionary Statement Regarding Forward-Looking Statements Certain information included herein may be deemed to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Forward-looking statements are often characterized by th |
|
| August 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2024 (Report No. 2) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addre |
|
| August 13, 2024 |
Exhibit 99.1 Inspira™ Approached by Large Medical Company to Evaluate Operation of their Key Product with INSPIRA™ ART100 – Results Exceed 100% at Maximum Flow Ra’anana, Israel – August 13, 2024 – Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (“Inspira”, “Inspira Technologies”, or the “Company”), a trailblazer in life-support technology, today announced that it was approached by a lea |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2024 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of principal |
|
| July 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2024 (Report No. 2) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address |
|
| July 30, 2024 |
Exhibit 99.1 Inspira™ Technologies Introduces the INSPIRA Cardi-ART, Aiming to Provide Oxygen to the Brain During Cardiac Arrest Inspira’s innovation targets life-saving intervention for patients with cardiac arrest, of which there are approximately 550,000 annual cardiac arrest events in the U.S., including 350,000 outside hospitals, where the survival rate is less than 10%. The INSPIRA Cardi-ART |
|
| July 11, 2024 |
Inspira™ Receives Israeli Regulatory Approval for the INSPIRA™ ART100 System Exhibit 99.1 Inspira™ Receives Israeli Regulatory Approval for the INSPIRA™ ART100 System Approval follows the FDA clearance announced on May 28, 2024 Ra’anana, Israel, July 11, 2024 – Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the “Company” or “Inspira”), a breakthrough medical technology company, is excited to announce the receipt of the Israeli Ministry of Health’s medical dev |
|
| July 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2024 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of principal e |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2024 (Report No. 4) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address |
|
| June 20, 2024 |
Inspira™ Announces Business Plan Targets Exhibit 99.1 Inspira™ Announces Business Plan Targets Company to aggressively promote INSPIRA™ ART100 in the U.S. and additional markets following FDA clearance, as well as accelerate plans for ground-breaking INSPIRA™ ART (Gen2) Ra’anana, Israel, June 20, 2024 – Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the “Company” or “Inspira”), a breakthrough medical technology company, ann |
|
| June 20, 2024 |
Exhibit 99.2 |
|
| June 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A (Amendment No. 1) REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2024 (Report No. 3) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366 |
|
| June 18, 2024 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-266748 PROSPECTUS SUPPLEMENT (To Prospectus dated August 18, 2022) 941,541 Ordinary Shares Pre-Funded Warrants to Purchase up to 1,709,760 Ordinary Shares 1,709,760 Ordinary Shares Underlying the Pre-Funded Warrants We are offering 941,541 ordinary shares, no par value (“Ordinary Shares” or the “Shares”). The purchase price of each Share is $1. |
|
| June 17, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 14, 2024, between Inspira Technologies OXY B.H.N. Ltd., a company organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers” |
|
| June 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2024 (Report No. 2) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address |
|
| June 17, 2024 |
PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT INSPIRA TECHNOLOGIES OXY B.H.N. LTD. Exhibit 4.1 PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT INSPIRA TECHNOLOGIES OXY B.H.N. LTD. Warrant Shares: Issue Date: June 18, 2024 Initial Exercise Date: June 18, 2024 THIS PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinaft |
|
| June 13, 2024 |
Inspira™ Receives First Ever Purchase Order for INSPIRA™ ART100 Systems in U.S. Exhibit 99.1 Inspira™ Receives First Ever Purchase Order for INSPIRA™ ART100 Systems in U.S. First units expected to be shipped in Q4 2024. The Purchase Order follows the recent FDA Clearance of the INSPIRA™ ART100. Ra’anana, Israel, June 13, 2024 – Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the “Company” or “Inspira”), a breakthrough medical technology company, today announced t |
|
| June 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2024 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of principal e |
|
| May 28, 2024 |
INSPIRA™ ART100 Receives FDA 510(k) Clearance Exhibit 99.1 INSPIRA™ ART100 Receives FDA 510(k) Clearance Ra’anana, Israel, May 28, 2024 – Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the “Company”, “Inspira”, or “Inspira Technologies”), a breakthrough medical technology company, today announced that it has received notification of 510(k) class II clearance from the U.S. Food and Drug Administration (FDA) for its INSPIRA™ ART10 |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2024 (Report No. 2) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address |
|
| May 22, 2024 |
Inspira Technologies OXY B.H.N. Ltd. 2 Ha-Tidhar St. Ra’anana 4366504, Israel Inspira Technologies OXY B.H.N. Ltd. 2 Ha-Tidhar St. Ra’anana 4366504, Israel May 22, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Inspira Technologies OXY B.H.N. Ltd. (CIK: 0001837493) Registration Statement No. 333-279276 on Form F-1 (the “Registration Statement”) Ladies and Gentlemen: Inspira Technologies OXY B.H.N |
|
| May 20, 2024 |
As filed with the Securities and Exchange Commission on May 20, 2024 As filed with the Securities and Exchange Commission on May 20, 2024 Registration No. |
|
| May 9, 2024 |
PLACEMENT AGENT ORDINARY SHARE PURCHASE WARRANT INSPIRA TECHNOLOGIES OXY B.H.N. LTD. Exhibit 4.8 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| May 9, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form F-1 (Form Type) Inspira Technologies Oxy B. |
|
| May 9, 2024 |
WARRANT TO PURCHASE ORDINARY SHARES INSPIRA TECHNOLOGIES OXY B.H.N. LTD. Exhibit 4.7 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| May 9, 2024 |
As filed with the Securities and Exchange Commission on May 9, 2024 As filed with the Securities and Exchange Commission on May 9, 2024 Registration No. |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2024 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of principal ex |
|
| May 2, 2024 |
Inspira™ Announces Start of Production of the INSPIRA™ ART100 Exhibit 99.1 Inspira™ Announces Start of Production of the INSPIRA™ ART100 Ra’anana, Israel, May 2, 2024 – Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the “Company” or “Inspira”), a breakthrough medical technology company, announced the start of production of the INSPIRA ART100 medical device. The INSPIRA ART100 device is being contract manufactured by a leading technology company |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2024 (Report No. 6) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addres |
|
| April 25, 2024 |
Inspira™ Receives CSA Certification of Compliance to U.S. Standards for the INSPIRA™ ART100 Exhibit 99.1 Inspira™ Receives CSA Certification of Compliance to U.S. Standards for the INSPIRA™ ART100 Ra’anana, Israel, April 25, 2024 – Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the “Company” or “Inspira”), a breakthrough medical technology company, announced that it has received the Canadian Standards Association (CSA) Certification of Compliance to U.S. standards for the I |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2024 (Report No. 5) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addres |
|
| April 17, 2024 |
Exhibit 99.1 Inspira™ Signs Term Sheet for Use of INSPIRA™ ART100 Device in Organ Transplant Procedures Ra’anana, Israel, April 16, 2024 – Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the “Company” or “Inspira”), a breakthrough medical technology company, is proud to announce the signing of a collaboration term sheet (the “Term Sheet”) with the Beilinson Hospital in Israel for the |
|
| April 10, 2024 |
Exhibit 99.1 Inspira™ and Ennocure In Vitro Study Results Show 100% Prevention of Bacterial Growth that Causes Bloodstream Infections Ra’anana, Israel, April 10, 2024 – Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the “Company” or “Inspira”), a breakthrough medical technology company, together with Ennocure MedTech Ltd. (“Ennocure”), announced results from their collaborative devel |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2024 (Report No. 4) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addres |
|
| April 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: April 2024 (Report No. 3) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addre |
|
| April 3, 2024 |
Exhibit 99.1 Inspira™ Announces Program to Pioneer the Applicable Use of the INSPIRA™ ART100 Device for an Artificial Womb Ra’anana, Israel, April 03, 2024 – Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the “Company” or “Inspira”), a breakthrough medical technology company, is delighted to announce the commencement of a program to explore the applicable use of the INSPIRA™ ART100 D |
|
| April 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2024 (Report No. 2) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addres |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2024 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of principal |
|
| April 1, 2024 |
Exhibit 99.1 Inspira™ Announces $1.65 Million Registered Direct Offering of Ordinary Shares by Inspira CEO’s Mother with Leading Fund Manager Ra’anana, Israel, April 1, 2024 – Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the “Company” or “Inspira”), today announced a strategic investment by leading investor, Mr. Ronen Juster, and the mother of Inspira’s Chief Executive Officer, Ms. |
|
| April 1, 2024 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-266748 PROSPECTUS SUPPLEMENT (To Prospectus dated August 18, 2022) 1,339,285 Ordinary Shares We are offering 1,339,285 ordinary shares, no par value (“Ordinary Shares” or the “Shares”). The purchase price of each Share is $1.232. The Shares are being sold in this offering to certain investors (the “Investors”) under a securities purchase agreem |
|
| April 1, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 28, 2024, between Inspira Technologies OXY B.H.N. Ltd., a company organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers |
|
| March 25, 2024 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2023 (the “Report”) by Inspira Technologies Oxy B.H.N. Ltd. (the “company”), the undersigned, as the Chief Financial Officer of the company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report fully co |
|
| March 25, 2024 |
Exhibit 2.1 Description of Securities The following description of the share capital of Inspira Technologies Oxy B.H.N. Ltd. (the “Company”, “we”, “us” or “our”), provisions of the Company’s articles of association, as they may be amended and restated from time to time (our “Articles”), and Israeli law are summaries and do not purport to be complete, and is qualified in its entirety by reference t |
|
| March 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. |
|
| March 25, 2024 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) Exhibit 12.2 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Yafit Tehila, certify that: 1. I have reviewed this annual report on Form 20–F of Inspira Technologies Oxy B.H.N. Ltd. (the “company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of th |
|
| March 25, 2024 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2023 (the “Report”) by Inspira Technologies Oxy B.H.N. Ltd. (the “company”), the undersigned, as the Chief Executive Officer of the company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report fully co |
|
| March 25, 2024 |
FORM OF AMENDMENT NO. 1 TO WARRANT AGENT AGREEMENT Exhibit 4.6 FORM OF AMENDMENT NO. 1 TO WARRANT AGENT AGREEMENT THIS AMENDMENT NO. 1 TO WARRANT AGENT AGREEMENT (this “Amendment”), is made and entered into as of August 8, 2022, by and among Inspira Technologies Oxy B.H.N. Ltd., an Israeli corporation (the “Company”), and VStock Transfer LLC, as warrant agent (“VStock”), and American Stock Transfer & Trust Company, LLC (“AST”). Capitalized terms u |
|
| March 25, 2024 |
Exhibit 97.1 INSPIRA TECHNOLOGIES OXY B.H.N. LTD (the “Company”) CLAWBACK POLICY Effective as of November 28, 2023 Background The Board of Directors of the Company (the “Board”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation |
|
| March 25, 2024 |
Exhibit 99.1 Inspira™ Technologies Reports Full Year 2023 Financial Results FDA Submission for approval of INSPIRA™ ART100 95% Accuracy Results for HYLA™ Blood Sensor Compared to Standard Blood Gas Analyzers Granted U.S. Patent for INSPIRA™ ART Medical Device Ra’anana, Israel, March 25, 2024 – Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the “Company” or “Inspira Technologies”), a b |
|
| March 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2024 (Report No. 6) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addres |
|
| March 25, 2024 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) Exhibit 12.1 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Dagi Ben-Noon, certify that: 1. I have reviewed this annual report on Form 20–F of Inspira Technologies Oxy B.H.N. Ltd. (the “company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of t |
|
| March 25, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Inspira Technologies Oxy B.H.N. Ltd. 2 Ha-Tidhar St. Rananna 4366504, Israel We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-259057) and Form F-3 (No. 333-266748) of Inspira Technologies Oxy B.H.N Ltd (“the Company”) of our report dated March 19, 2024, relating to the finan |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2024 (Report No. 5) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addres |
|
| March 18, 2024 |
Exhibit 99.1 Inspira™ Announces AMAR Regulatory Submission of the INSPIRA™ ART100, to Enter the Southeast Asia and South American Markets Ra’anana, Israel, March 18, 2024 – Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the “Company” or “Inspira”), a breakthrough medical technology company, is excited to announce the AMAR submission for approval of the INSPIRA™ ART100, marking a sign |
|
| March 15, 2024 |
As filed with the Securities and Exchange Commission on March 15, 2024 As filed with the Securities and Exchange Commission on March 15, 2024 Registration No. |
|
| March 15, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Inspira Technologies Oxy B. |
|
| March 12, 2024 |
Exhibit 99.1 Inspira™ Releases New Data Demonstrating Superiority of its Core Technology, Across Key Endpoints of HMSS Indicator · An unprecedented achievement of a zero pressure gradient measured when using the VORTX™ device, directly correlating with a decrease in markers of blood damage. · The performance of the VORTX™, tested according to a regulatory guideline, was found to meet 100% of blood |
|
| March 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2024 (Report No. 4) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addres |
|
| March 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: March 2024 (Report No. 3) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addre |
|
| March 8, 2024 |
INSPIRA TECHNOLOGIES OXY B.H.N. Ltd. NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Exhibit 99.1 INSPIRA TECHNOLOGIES OXY B.H.N. Ltd. NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that an Extraordinary General Meeting of Shareholders (the “Meeting”) of Inspira Technologies Oxy B.H.N. Ltd. (“Inspira Technologies” or the “Company”) will be held on Monday, April 8, 2024, at 4:00 p.m. Israel time, at the Company’s office, located at 2 Ha-Tidhar Street |
|
| March 4, 2024 |
INSPIRA TECHNOLOGIES OXY B.H.N. Ltd. NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Exhibit 99.1 INSPIRA TECHNOLOGIES OXY B.H.N. Ltd. NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that an Extraordinary General Meeting of Shareholders (the “Meeting”) of Inspira Technologies Oxy B.H.N. Ltd. (“Inspira Technologies” or the “Company”) will be held on Monday, April 8, 2024, at 4:00 p.m. Israel time, at the Company’s office, located at 2 Ha-Tidhar Street |
|
| March 4, 2024 |
Exhibit 99.1 Inspira™ Announces Plans to Report the Primary Results for a Core Blood Oxygenation Technology Within Days ● The major milestone refers to Inspira’s proprietary technology to oxygenate blood for the INSPIRA™ ART (Gen 2). This patented tech is considered by Inspira to be a game-changer and also aims to replace technologies used today by current medical device companies. ● Anticipated U |
|
| March 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2024 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of principal |
|
| March 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: March 2024 (Report No. 2) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addre |
|
| February 27, 2024 |
Exhibit 99.1 Inspira™ Announces Breakthrough Update: Nears First FDA 510(k) Approval, 3 U.S. Patents Approved, $546 million in Summary Distribution Agreements Ra’anana, Israel, February 27, 2024 – Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the “Company” or “Inspira Technologies”), a breakthrough medical technology company, has announced that the Company is progressing towards 510 |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2024 (Report No. 4) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Add |
|
| February 27, 2024 |
Exhibit 99.3 Copyright © 2018 - 2024 Inspira Technologies OXY B.H.N. LTD., All rights reserved 1 INVESTOR DECK I FEBRUARY 2024 EMPOWERED BREATHING WITHOUT LUNGS See Disclaimers on slides 1 - 16. Copyright © 2018 - 2024 Inspira Technologies OXY B.H.N. LTD., All rights reserved 2 This presentation contains express or implied forward - looking statements pursuant to U . S . Federal securities laws . |
|
| February 27, 2024 |
Inspira™ To Host Conference Call to Discuss Investor Presentation and Announce Next Major Milestone Exhibit 99.2 Inspira™ To Host Conference Call to Discuss Investor Presentation and Announce Next Major Milestone Ra’anana, Israel, February 27, 2024 – Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the “Company” or “Inspira Technologies”), a breakthrough medical technology company, announced today that the Company President, Director and co-founder, Mr. Joe Hayon, will present an Inv |
|
| February 22, 2024 |
Exhibit 99.1 Inspira™ introduces high-end platform for bio-mimicking blood parameters for development and testing of core technologies Ra’anana, Israel, February 22, 2024 – Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the “Company” or “Inspira Technologies”), a breakthrough medical technology company targeting to supersede mechanical ventilators, has unveiled an exclusive in-house |
|
| February 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2024 (Report No. 3) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Add |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2024 (Report No.2) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addr |
|
| February 14, 2024 |
Inspira™ Receives First Ever U.S. Patent Approval for an Orbiting Blood Oxygenation Delivery System Exhibit 99.1 Inspira™ Receives First Ever U.S. Patent Approval for an Orbiting Blood Oxygenation Delivery System 94% of the Claims Were Found to be Novel Ra’anana, Israel, February 14, 2024 – Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the “Company” or “Inspira Technologies”), is a breakthrough medical technology company targeting to supersede mechanical ventilators, has received |
|
| February 14, 2024 |
IINN / Inspira Technologies Oxy B.H.N. Ltd. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-iinn123123.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* INSPIRA TECHNOLOGIES OXY B.H.N. LTD. (Name of Issuer) Ordinary Shares, no par value (Title of Class of Securities) M53637100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the |
|
| February 12, 2024 |
SC 13G/A 1 ea193289-13ga1hayoninspira.htm AMENDMENT NO. 1 TO SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 1) (Rule 13d-102) Under the Securities Exchange Act of 1934 Inspira Technologies Oxy B.H.N. Ltd. (Name of Issuer) Ordinary Shares (Title of Class of Securities) M53637100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Fili |
|
| February 12, 2024 |
SC 13G/A 1 ea193288-13ga1beninspira.htm AMENDMENT NO. 1 TO SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 1) (Rule 13d-102) Under the Securities Exchange Act of 1934 Inspira Technologies Oxy B.H.N. Ltd. (Name of Issuer) Ordinary Shares (Title of Class of Securities) M53637100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing |
|
| February 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2024 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of princip |
|
| February 8, 2024 |
Exhibit 99.1 Inspira™ Technologies Collaborates with a Leading Israeli Medical Center for Clinical Evaluation of INSPIRA™ ART Device The parties have entered a non-binding Letter of Intent RA’ANANA, Israel, February 08, 2024 – Inspira Technologies OXY BHN Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the “Company” or “Inspira”), a pioneer in life support technology with a vision to supersede traditional me |
|
| January 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2024 (Report No. 3) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addr |
|
| January 30, 2024 |
Exhibit 99.1 Inspira™ Technologies Signs Strategic Agreement to Enter Gulf States with Glo-Med for Deployment of 531 INSPIRA™ ART Devices The agreement to potentially provide Inspira Technologies with $32.6 million over a 5-year period, subject to regulatory approvals RA’ANANA, Israel, January 30, 2024 – Inspira Technologies OXY B.H.N Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the “Company” or “Inspira |
|
| January 9, 2024 |
Exhibit 99.1 Inspira™ Announces Plans to Launch and Target Single-Use Disposable Blood Oxygenation Kit for a New Disposable Perfusion Market Opportunity The kit is being designed for the INSPIRA™ ART device series and is intended to be compatible with various life support machines sold in the market RA’ANANA, Israel, January 9, 2024 – Inspira Technologies OXY B.H.N Ltd. (Nasdaq: IINN) (Nasdaq: IIN |
|
| January 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2024 (Report No. 2) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addr |
|
| January 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2024 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of principa |
|
| January 2, 2024 |
Exhibit 99.1 Inspira™ Technologies Signs Letter of Intent with Northwestern Memorial Hospital in Chicago for Clinical Use of INSPIRA™ ART100 Device RA’ANANA, Israel, January 2, 2024 – Inspira Technologies OXY B.H.N Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the “Company” or “Inspira Technologies”), a pioneer in life support technology with a vision to supersede traditional mechanical ventilators, has an |
|
| December 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: December 2023 (Report No. 4) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Ad |
|
| December 28, 2023 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-266748 PROSPECTUS SUPPLEMENT (To Prospectus dated August 18, 2022) 1,375,000 Ordinary Shares Pre-Funded Warrants to Purchase up to 1,656,250 Ordinary Shares 1,656,250 Ordinary Shares Underlying the Pre-Funded Warrants We are offering 1,375,000 ordinary shares, no par value (“Ordinary Shares” or the “Shares”). The purchase price of each Share is |
|
| December 27, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 26, 2023, between Inspira Technologies OXY B.H.N. Ltd., a company organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchas |
|
| December 27, 2023 |
ORDINARY SHARE PURCHASE WARRANT INSPIRA TECHNOLOGIES OXY B.H.N. LTD. Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| December 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2023 (Report No. 3) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Add |
|
| December 27, 2023 |
PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT Inspira Technologies OXY B.H.N. Ltd. Exhibit 4.2 PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT Inspira Technologies OXY B.H.N. Ltd. Warrant Shares: Issue Date:, 2023 Initial Exercise Date: , 2023 THIS PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, a |
|
| December 27, 2023 |
Inspira Announces $3.88 Million Registered Direct Offering Exhibit 99.1 Inspira Announces $3.88 Million Registered Direct Offering Ra’anana, Israel, December 26, 2023 – Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the “Company” or “Inspira”), a pioneer in life support technology with a vision to supersede traditional mechanical ventilators, today announced that it has entered into a definitive agreement for the issuance and sale of an aggre |
|
| December 26, 2023 |
Exhibit 99.1 Inspira™ Announces 95% Accuracy Results for HYLA™ Blood Sensor, Planning FDA Submission for Clearance in 2024 RA’ANANA, Israel, December 26, 2023 – Inspira Technologies OXY BHN Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the “Company” or “Inspira”), a pioneer in life support technology with a vision to supersede traditional mechanical ventilators, today announced a significant advancement in |
|
| December 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2023 (Report No.2) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addr |
|
| December 11, 2023 |
Exhibit 99.1 In Preparation for FDA Clearance and Device Deployment, Inspira has Appointed Dr. Dan Gorfil to Medical Advisory Board Ra’anana, Israel, December 11, 2023 – Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the “Company” or “Inspira”), a pioneer in life support technology with a vision to supersede traditional mechanical ventilators, is pleased to announce the appointment of |
|
| December 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2023 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of princip |
|
| November 29, 2023 |
Exhibit 99.1 Inspira Collaborates with Ennocure for Development of Proprietary Bio-Electronic Treatment to Prevent Associated Bloodstream Infections in ICU Patients Ra’anana, Israel, November 29, 2023 – Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the “Company” or “Inspira”), an innovator in life support technology, is excited to announce a partnership with Ennocure MedTech Ltd. (“E |
|
| November 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2023 (Report No. 5) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Add |
|
| November 22, 2023 |
INSPIRA TECHNOLOGIES OXY B.H.N. Ltd. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS Exhibit 99.1 INSPIRA TECHNOLOGIES OXY B.H.N. Ltd. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that an Annual General Meeting of Shareholders (the “Meeting”) of Inspira Technologies Oxy B.H.N. Ltd. (“Inspira Technologies” or the “Company”) will be held on December 27, 2023, at 4:00p.m. Israel time at the Company’s office, located at 2 Ha-Tidhar Street, Ra’anana 4366504, |
|
| November 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: November 2023 (Report No. 4) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Ad |
|
| November 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: November 2023 (Report No. 3) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Ad |
|
| November 16, 2023 |
Exhibit 99.1 Inspira™ Technologies Reports Third Quarter 2023 Financial Results Ra’anana, Israel, November 16, 2023 – Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the “Company” or “Inspira”), a pioneer in acute respiratory care, today announced its financial results for the third quarter ended September 30, 2023. This quarter, Inspira continued to progress in the development of its |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2023 (Report No. 2) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Add |
|
| November 7, 2023 |
Exhibit 99.1 Inspira™ Announces Israeli Innovation Authority Grant for New VORTX™ Disposable Blood Oxygenation Technology Inspira’s VORTX is a potential frontrunner in the $4 billion disposable blood oxygenator market Ra’anana, Israel, November 6, 2023 – Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the “Company” or “Inspira Technologies”), a company dedicated to transforming the mu |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2023 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of princip |
|
| October 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2023 (Report No. 4) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addr |
|
| October 25, 2023 |
INSPIRA TECHNOLOGIES OXY B.H.N LTD. Filed Pursuant to Rule 424(b)(3) Registration No. 333-266748 SUPPLEMENT NO. 1 TO PROSPECTUS SUPPLEMENT DATED APRIL 4, 2023 (to Prospectus dated August 18, 2022) INSPIRA TECHNOLOGIES OXY B.H.N LTD. This Supplement No. 1 to Prospectus Supplement, or this Supplement No. 1, amends and supplements the information in the prospectus, dated August 18, 2022, or the Prospectus, to the registration statement |
|
| October 25, 2023 |
Inspira™ Granted U.S. Patent for INSPIRA™ ART500 Medical Device Exhibit 99.1 Inspira™ Granted U.S. Patent for INSPIRA™ ART500 Medical Device This new patent advances Inspira’s ability to enter into the Company estimated $20 billion market as a potential innovative frontrunner with planned global deployments of its exclusive INSPIRA ART500 and disruptive technology. Ra’anana, Israel, October 25, 2023 – Inspira™ Technologies OXY BHN Ltd. (Nasdaq: IINN, IINNW) (t |
|
| October 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2023 (Report No. 3) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addr |
|
| October 24, 2023 |
Inspira™ Terminates ATM Program and Provides an Update Exhibit 99.1 Inspira™ Terminates ATM Program and Provides an Update Ra’anana, Israel, October 24, 2023 – Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) - (“Inspira Technologies” or “the Company”), a company dedicated to advancing acute respiratory care by enabling breathing without lungs, today announces the termination of its at-the-market (ATM) equity offering program originally ann |
|
| October 10, 2023 |
Exhibit 99.1 Inspira™ Enters into a Distribution Agreement in Central America with CIO MED GROUP The agreement to potentially generate $28 million, mainly in recurring revenues from disposable kits over a five year period following a regulatory approval Ra’anana, Israel, October 10, 2023 – Inspira™ Technologies OXY BHN Ltd. (Nasdaq: IINN, IINNW) (the “Company” or “Inspira Technologies”), a company |
|
| October 10, 2023 |
As filed with the Securities and Exchange Commission on October 10, 2023 As filed with the Securities and Exchange Commission on October 10, 2023 Registration No. |
|
| October 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2023 (Report No. 2) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addr |
|
| October 2, 2023 |
Exhibit 99.1 INSPIRA TECHNOLOGIES OXY B.H.N. LTD. INTERIM CONDENSED FINANCIAL STATEMENTS AS OF JUNE 30, 2023 UNAUDITED INSPIRA TECHNOLOGIES OXY B.H.N. LTD. (UNAUDITED) TABLE OF CONTENTS Page Interim condensed statements of financial position 1-2 Interim condensed statements of comprehensive loss 3 Interim condensed statements of changes in shareholders’ equity 4 Interim condensed statements of cas |
|
| October 2, 2023 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Cautionary Statement Regarding Forward-Looking Statements Certain information included herein may be deemed to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Forward-looking statements are often characterized by th |
|
| October 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2023 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of principa |
|
| September 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2023 (Report No. 2) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Ad |
|
| September 28, 2023 |
Exhibit 99.1 Inspira™ Technologies Unveils the INSPIRA™ ART Line of Medical Devices at the World’s Largest Extracorporeal Life Support Conference The ELSO conference brings together healthcare institutions, researchers, and industry partners Ra’anana, Israel, September 28, 2023 – Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the “Company” or “Inspira Technologies”), a company aiming |
|
| September 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2023 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of princi |
|
| September 13, 2023 |
Exhibit 99.1 InspiraTM Announces 510(k) FDA Submission of INSPIRATM ART100 Towards Commercialization Management estimates FDA clearance within approximately 6 months Ra'anana, Israel, September 13, 2023 – Inspira™ Technologies OXY BHN Ltd. (Nasdaq: IINN, IINNW) (the "Company" or "Inspira Technologies"), a company aiming to bring a paradigm shift to acute respiratory care by empowering breathing wi |
|
| August 29, 2023 |
Exhibit 99.1 Inspira™ Signs Agreement Expansion with Innovimed for Clinical Trials of INSPIRA™ ART Respiratory Medical Devices The extended agreement covers any European country Ra’anana, Israel, August 29, 2023 – Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the “Company” or “Inspira”), a company dedicated to advancing acute respiratory care by enabling breathing without lungs, ann |
|
| August 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2023 (Report No.3) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addres |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2023 (Report No. 2) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addre |
|
| August 10, 2023 |
Exhibit 99.1 Inspira™ Technologies Reports Second Quarter 2023 Financial Results As of June 30, 2023, the Company had $8.9 million in cash, cash equivalents and short-term bank deposits. Ra’anana, Israel, August 10, 2023 – Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the “Company” or “Inspira”), a company aiming to revolutionize acute respiratory care, announced today its financial |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2023 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of principal |
|
| August 9, 2023 |
ART100 Completes Usability Study in Boston Massachusetts, U.S. Exhibit 99.1 INSPIRATM ART100 Completes Usability Study in Boston Massachusetts, U.S. Ra’anana, Israel, August 9, 2023 – Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the “Company” or “Inspira Technologies”), a company aiming to revolutionize acute respiratory care by empowering breathing without lungs, is proud to announce it has completed a Usability Study in Boston, Massachusetts |
